Issue represents a potential threat in fighting future pandemics.
Kevin E. Noonan, PhD
Advertisement
Partner with IP law firm MBHB and the co-chair of its biotechnology and pharmaceuticals practice group
Articles by Kevin E. Noonan, PhD
Kevin E. Noonan asks, what do the biosimilars provisions of the Trans-Pacific Partnership portend for global biologic drug development?
Advertisement
Latest Updated Articles
Global Biologic Drug Development and the TTPPublished: January 25th 2016 | Updated: November 15th 2020
Advertisement
Advertisement
Trending on PharmExec
1
Real-World Data Brings New Insights to Natural History of Disease Studies
2
FDA Approves Hernexeos Under National Priority Voucher Program
3
Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya
4
Alkermes Reveals CEO Succession Plan Following Richard Pops’ Retirement Announcement
5